WO2015073598A1 - Extracts of rosemary or hemerocallis fulva and methods of using same to promote circadian rhythm - Google Patents
Extracts of rosemary or hemerocallis fulva and methods of using same to promote circadian rhythm Download PDFInfo
- Publication number
- WO2015073598A1 WO2015073598A1 PCT/US2014/065336 US2014065336W WO2015073598A1 WO 2015073598 A1 WO2015073598 A1 WO 2015073598A1 US 2014065336 W US2014065336 W US 2014065336W WO 2015073598 A1 WO2015073598 A1 WO 2015073598A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- protein
- hours
- rosemary
- expression
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 230000027288 circadian rhythm Effects 0.000 title claims abstract description 46
- 240000009206 Hemerocallis fulva Species 0.000 title claims abstract description 42
- 235000002941 Hemerocallis fulva Nutrition 0.000 title claims abstract description 42
- 239000002714 Extracts of rosemary Substances 0.000 title description 4
- 235000019306 extracts of rosemary Nutrition 0.000 title description 4
- 239000000284 extract Substances 0.000 claims abstract description 139
- 230000014509 gene expression Effects 0.000 claims abstract description 90
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 90
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 78
- 230000008569 process Effects 0.000 claims abstract description 50
- 102100037315 F-box/LRR-repeat protein 3 Human genes 0.000 claims abstract description 30
- 102100027753 Putative F-box/LRR-repeat protein 21 Human genes 0.000 claims abstract description 26
- 102000000344 Sirtuin 1 Human genes 0.000 claims abstract description 25
- 108010041191 Sirtuin 1 Proteins 0.000 claims abstract description 25
- 108010088547 ARNTL Transcription Factors Proteins 0.000 claims abstract description 20
- 102000008867 ARNTL Transcription Factors Human genes 0.000 claims abstract description 19
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 16
- 244000178231 Rosmarinus officinalis Species 0.000 claims abstract description 12
- 101001026868 Homo sapiens F-box/LRR-repeat protein 3 Proteins 0.000 claims abstract 7
- 101000862167 Homo sapiens Putative F-box/LRR-repeat protein 21 Proteins 0.000 claims abstract 7
- 230000001965 increasing effect Effects 0.000 claims description 30
- 229940096998 ursolic acid Drugs 0.000 claims description 28
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 28
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 108010075228 CLOCK Proteins Proteins 0.000 claims description 16
- 102000008025 CLOCK Proteins Human genes 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 102000011990 Sirtuin Human genes 0.000 claims description 6
- 108050002485 Sirtuin Proteins 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 7
- 239000013543 active substance Substances 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 82
- 235000020748 rosemary extract Nutrition 0.000 description 55
- 229940092258 rosemary extract Drugs 0.000 description 55
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 55
- 241001529742 Rosmarinus Species 0.000 description 33
- 239000000203 mixture Substances 0.000 description 24
- 101710083635 F-box/LRR-repeat protein 3 Proteins 0.000 description 23
- 238000000605 extraction Methods 0.000 description 23
- 101710126388 F-box/LRR-repeat protein 21 Proteins 0.000 description 19
- 230000002060 circadian Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 230000010410 reperfusion Effects 0.000 description 11
- 238000010166 immunofluorescence Methods 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- XLIJUKVKOIMPKW-BTVCFUMJSA-N [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XLIJUKVKOIMPKW-BTVCFUMJSA-N 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000000306 component Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- -1 CLOCK Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000005945 translocation Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 239000003855 balanced salt solution Substances 0.000 description 4
- 230000008632 circadian clock Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000002730 additional effect Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000034512 ubiquitination Effects 0.000 description 3
- 238000010798 ubiquitination Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100038419 Circadian locomoter output cycles protein kaput Human genes 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102000018700 F-Box Proteins Human genes 0.000 description 2
- 108091072033 F-box protein family Proteins 0.000 description 2
- 241000756137 Hemerocallis Species 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100037211 Aryl hydrocarbon receptor nuclear translocator-like protein 1 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- 101710197111 Circadian locomoter output cycles protein kaput Proteins 0.000 description 1
- 108010037139 Cryptochromes Proteins 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 101000831686 Drosophila melanogaster Protein cycle Proteins 0.000 description 1
- 108700011215 E-Box Elements Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 244000207620 Euterpe oleracea Species 0.000 description 1
- 235000012601 Euterpe oleracea Nutrition 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000740484 Homo sapiens Aryl hydrocarbon receptor nuclear translocator-like protein 1 Proteins 0.000 description 1
- 101000882921 Homo sapiens Circadian locomoter output cycles protein kaput Proteins 0.000 description 1
- 101000640050 Homo sapiens Protein strawberry notch homolog 1 Proteins 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000021272 Laurelia serrata Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000234269 Liliales Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000896229 Mus musculus Aryl hydrocarbon receptor nuclear translocator-like protein 1 Proteins 0.000 description 1
- 101001073214 Mus musculus Period circadian protein homolog 2 Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010047728 Period Circadian Proteins Proteins 0.000 description 1
- 102000007001 Period Circadian Proteins Human genes 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000205407 Polygonum Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101100496572 Rattus norvegicus C6 gene Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102000000477 Sirtuin 2 Human genes 0.000 description 1
- 108010041216 Sirtuin 2 Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000003650 acai Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 244000307585 akino wasuregusa Species 0.000 description 1
- 235000006822 akino wasuregusa Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 244000288972 chang guan xuan cao Species 0.000 description 1
- 235000006147 chang guan xuan cao Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 description 1
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007946 glucose deprivation Effects 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 125000002220 ursolic acid group Chemical group 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Definitions
- the present invention relates to dietary supplement compositions containing rosemary or Hemerocallis fulva extracts and methods for promoting or maintaining or modulating protein expression or circadian rhythm.
- Circadian rhythms control a variety of biological processes, including sleep/wake cycles, body temperature, hormone secretion, gastrointestinal function, metabolic glucose homeostasis, and immunological functions.
- Biological clocks exhibiting circadian rhythms exist in virtually all tissues, with a series of clock genes generating the rhythm through protein feedback effects on their own synthesis.
- CLOCK-BMAL1 is a core component of the molecular clock machinery that drives circadian gene expression and physiology in mammals.
- CLOCK and BMALl are each basic helix-loop-helix (bHLH) PAS- domain transcription factors that together form the positive elements of the central oscillatory loop.
- CLOCK and BMALl form a heterodimer that binds to E-box elements in the promoters of target genes.
- CLOCK:BMALl Some of the primary genes under transcriptional control by CLOCK:BMALl encode the three Period (mPerl, mPer2, and mPer3) proteins and two Cryptochromegenes (mCryl and mCryl) proteins. Following translation of the Per and Cry proteins, they translocate to the nucleus where they act as potent inhibitors of CLOCK:BMALl -induced gene transcription forming a negative feedback loop and regulating the rhythmic expression of many genes.
- the PERIOD protein mPER2 the gene of which is also under CLOCK:BMALl transcriptional control, functions as a stimulator of Bmal 1 transcription, forming the positive feedback loop and enhancing CLOCK:BMALl activity. The regulation of these positive and negative feedback loops regulates the circadian rhythm within the cell.
- SIRT1 a nicotinamide adenine dinucleotide-dependent sirtuin
- CLOCK circadian rhythm
- SIRT1 controls circadian clock circuitry and promotes cell survival providing a connection with age- related neoplasms.
- circadian function decays with aging in normal mice, and boosting their SIRTl levels in the brain could prevent this decay.
- loss of SIRT1 function impairs circadian control in young mice, mimicking what happens in normal aging.
- SIRTl has been shown to exert this control by regulating the genes BMAL1 and CLOCK, the two major keepers of the central circadian clock.
- Oxygen and circadian rhythmicity are essential in a myriad of physiological processes to maintain homeostasis, from blood pressure and sleep/wake cycles, as well as in cellular signaling pathways that play critical roles in health and disease. Oxidative stress can induce the dysregulated circadian rhythms. Thus, there is a need for new compositions and methods for regulating proper protein expression and circadian rhythm.
- processes of altering an expression characteristic of a CLOCK, BMALl, FBXL3, FBXL21, or SIRTl protein in a subject including: administering to said subject an effective amount of an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof at an administration time, said effective amount comprising ursolic acid at 10% or greater by weight; where the administering occurs at or between -4 hours to 12 hours after light exposure.
- the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10- 14 hours after light exposure, optionally at or between -4 hours to 0 hours prior to light exposure.
- processes of altering an expression characteristic of a circadian rhythm protein in a subject including administering to said subject an effective amount of an extract of rosemary, an extract of hemerocallis fulva, an active portion or component thereof, or combinations thereof at an administration time, where the administration time occurs such that the extract, an active portion or component thereof, or combinations thereof contacts a cell having a circadian rhythm thereby increasing the expression of CLOCK, BMALl, FBXL3, FBXL21, SIRTl, or combinations thereof in said cell.
- an extract is a water extract. In some aspects, an extract is a component of a dietary supplement.
- Administration is optionally once daily, twice daily, more frequently, or on an as needed basis.
- Administration optionally occurs at or between -4 hours to 12 hours after light exposure.
- the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10-14 hours after light exposure, optionally at or between -4 hours to 0 hours prior to light exposure.
- An extract in any of the processes optionally includes 10% or greater ursolic acid, optionally 25% or greater ursolic acid.
- Also provided are processes of altering an expression characteristic of a circadian rhythm protein in a subject including administering to a subject, where the administration time occurs such that said ursolic acid contacts a cell having a circadian rhythm thereby increasing the expression of CLOCK, BMALl, FBXL3, FBXL21, SIRTl, or combinations thereof in said subject.
- the ursolic acid is optionally obtained from extracting the ursolic acid from rosemary, hemerocallis fulva, or combinations thereof with water, an alcohol or combinations thereof.
- the ursolic acid is optionally administered once daily, twice daily, more frequently, or on an as needed basis.
- Administration optionally occurs at or between -4 hours to 12 hours after light exposure.
- the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10-14 hours after light exposure, optionally at or between -4 hours to 0 hours prior to light exposure.
- a subject is optionally in need of improved expression of a circadian rhythm gene or protein, optionally due to exposure to a stress or other environmental condition that reduces expression of a circadian rhythm gene or protein such as CLOCK, BMAL1, FBXL3, FBXL21, SIRT1, or combinations thereof.
- FIG. 1 A illustrates the effects of RME and HFE on CLOCK protein expression in C6 cells
- FIG. IB illustrates the effects of RME and HFE on CLOCK protein expression in C6 cells
- FIG. 2A illustrates RME increased BMAL1 protein levels in 4hr oxygen-glucose deprivation (OGD) and 2hr reperfusion treated C6 cells;
- FIG. 2B illustrates RME increased FBXL21 protein levels in 4hr oxygen-glucose deprivation (OGD) and 2hr reperfusion treated C6 cells;
- FIG. 3 A illustrates SIRT1 levels increased in OGD Rat L-6 cells treated with RME, HFE, or both;
- FIG. 3B illustrates quantifiable increases in SIRTl levels in OGD treated Rat L-6 cells
- FIG. 4A illustrates CLOCK protein levels increased in OGD Rat L-6 cells treated with RME, HFE, or both;
- FIG. 4B illustrates quantifiable increases in CLOCK levels in OGD treated Rat L-6 cells by RME, HFE, or both;
- FIG. 5 A illustrates Bmall protein levels increased in OGD Rat L-6 cells treated with RME, HFE, or both;
- FIG. 5B illustrates quantifiable increases in Bmall levels in OGD treated Rat L-6 cells by RME, HFE, or both; DETAILED DESCRIPTION OF ASPECTS OF THE INVENTION
- Altering a circadian rhythm is understood as altering, optionally increasing, the expression level, post- translational modification state, nuclear or cytoplasmic location or translocation, or RNA expression rate of a protein normally involved in a 24-hour or other regular cycle in one or more cell types in a subject.
- a process includes administering to a subject an effective amount of an extract of rosemary (RME), an extract of hemerocallis fulva (HFE), active portion or component thereof, or combinations thereof or a dietary supplement containing in whole or in part of an extract of rosemary, an extract of hemerocallis fulva, active portion or component thereof, or combinations thereof. Such an administration is at an administration time.
- the administration of the extract of rosemary, an extract of hemerocallis fulva, active portion thereof, or combinations thereof or a dietary supplement containing such will alter an expression characteristic of a protein of CLOCK, BMAL1, FBXL3, FBX121, SIRT1, or combinations thereof in the subject.
- the invention has utility for altering or adjusting one or more expression characteristics of a protein involved in a circadian rhythm in a cell.
- An "expression characteristic" is the transcription of a gene encoding a circadian rhythm protein, translation of RNA encoding a circadian rhythm protein, localization of RNA encoding a circadian rhythm protein, protein function, protein localization, protein post- translational modification, or other parameter recognized in the art related to protein expression and function.
- the invention provides materials in the form of botanical extracts, such as an extract of rosemary, an extract of hemerocallis fulva, active portion thereof, or combinations thereof, alone or as part of a dietary supplement that have utility for altering one or more expression characteristics of a protein involved in a circadian rhythm in a subject.
- the extract, active portion thereof, or dietary supplement may be in pharmaceutical dietary supplement composition in solid, semi-solid, or liquid dosage forms, such as, for example, tablets, chewables, suppositories, pills, capsules, powders, liquids, or suspensions, and may be provided in unit dosages suitable for a single administration. Time release preparations are also contemplated as effective dosage formulations.
- compositions may include an effective amount of a selected extract of rosemary, hemerocallis fulva, active portion thereof, or combinations, optionally in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, or diluents.
- the extracts are recognized to include an active ingredient as an active portion of an extract, or the sole portion of an extract.
- Active ingredient refers a component present in the extract that renders, directly or indirectly, the intended effect of the extract.
- an active ingredient is ursolic acid.
- Extraction parameters such as water quality, heating temperature, drying temperature, heating time, drying time, and filtering processes all contribute to the quality and efficiency of the process. Water quality directly affects the concentration of active ingredient(s). Poor quality water may cause active ingredient(s) to become decomposed or oxidized during or following the extraction process.
- the rosemary or hemerocallis fulva may be obtained from various resources.
- Rosemary, or Rosmarinus officinalis is a woody bush native to the Mediterranean region. Extracts of rosemary may be made from Rosmarinus spp. and preferably from the leaves and young flowering tops of fresh rosemary (Rosmarinus officinalis L. and its cultivars). Rosemary extraction may be performed by harvesting the leaves of a rosemary plant and reducing them in size such as by chopping to improve solvent penetration.
- a typical particle size is optionally 0.5 - 5.0 mm, or any value or range therebetween.
- the leaf is chopped into a powder type substance with a particle size of less than 0.5 mm.
- the chopped plant material is combined with a suitable extraction solvent such as water and/or a low molecular weight alcohol (e.g. C 4 - Ce alcohol) such as ethanol.
- a suitable extraction solvent such as water and/or a low molecular weight alcohol (e.g. C 4 - Ce alcohol) such as ethanol.
- the plant material is combined with the solvent for an extraction time of 18 to 36 hours.
- the extraction temperature is optionally the range 10°C to 45°C.
- the resulting extract liquid is separated from the solid material and filtered, optionally with a sterile filter.
- the resulting extract is poured onto nonstick tray and allowed to dry at 80- 90°C. Vacuum-spray dry equipment is optionally used for the drying procedure.
- the resulting dry extract powder is weighed.
- An extraction ratio is calculated as w/20 xl00% with w as the weight (g) of the dry extract powder.
- the sample and water ratio, heat time, volume of water in the second extraction may vary depending on the
- Extracts of Hemerocallis fulva are optionally obtained from extraction in an extraction solvent such as water and/or low molecular weight alcohol such as ethanol. Extracts are prepared from plants belonging to the genus Hemerocallis of the family Liliaceae of the order Liliales are used. Examples of such plants include Akinowasuregusa ⁇ Homerocallis fulva L. sempervirens M. Hotta or Homerocallis sempervirens Araki), Honkanzo (Hemerocallis fulva L. var. fulva), Nokanzo (Hemerocallis fulva L. var.
- An extract is optionally prepared from whole plants or plant parts, such as leaves, stems, and roots.
- an extract is prepared by drying the plant material and optionally cutting the material into a suitable size for extraction, such as the sizes described for rosemary.
- the plant material is combined with an extraction solvent (e.g. water, aqueous buffer, low molecular weight alcohol, or combinations thereof) that is preheated to a temperature of 60°C to 100°C for an extraction time, typically of 20 to 90 minutes.
- the particulate material is then removed by gravity separation, centrifugatkm, or filtering, optionally with a filter size suitable for aseptic filtration.
- the resulting extract is optionally poured onto nonstick tray and allowed to dry at 80-90°C. Vacuum-spray dry equipment is optionally used for the drying procedure.
- the resulting dry extract powder is weighed. An extraction ratio is calculated as w/20 xl00% with w as the weight (g) of the dry extract powder.
- the sample and water ratio, heat time, volume of water in the extraction may vary depending on the amount of the raw material used for extraction.
- a second extraction of either plant material is performed optionally using the same extraction parameters or differing extraction parameters.
- a second extraction is performed in a low molecular weight alcohol optionally of C2-C4.
- the first and second extraction solutions are optionally combined together and dried.
- an extract includes or consists of ursolic acid as an active ingredient.
- Ursolic acid is optionally present in an extract at a concentration of 10 weight percent or greater.
- ursolic acid is present in an extract at a concentration of 25 weight percent or greater.
- ursolic acid is present at a weight percent at or in excess of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, or 99.9.
- ursolic acid is descried as a component of or the product representing an extract
- extract may in some aspects include otherwise isolated, purified, or chemically synthesized ursolic acid.
- an "extract” is in some aspects ursolic acid obtained either by extraction from a natural or non-natural source, or used as a chemically synthesized ursolic acid.
- the extract can be in pharmaceutical compositions in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, or suspensions, and may be provided in unit dosages suitable for a single administration. Time release preparations are specifically contemplated as effective dosage formulations.
- the compositions will include an effective amount of the selected extract in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, or diluents.
- conventional nontoxic solid carriers may include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talc, cellulose, glucose, sucrose and magnesium carbonate.
- Liquid pharmaceutically administrable compositions may, for example, be prepared by dissolving or dispersing an active compound with optimal pharmaceutical adjuvants in an excipient, such as water, saline, aqueous dextrose, glycerol, or ethanol, to form a solution or suspension.
- the pharmaceutical composition may contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, for example, sodium acetate or triethanolamine oleate. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's The Science and Practice of Pharmacy (20 th Edition).
- fine powders or granules of extract, or a liquid extract may contain diluting, dispersing, or surface active agents.
- the extract may be presented in water or in syrup, in capsules or sachets in the dry state, or in a non-aqueous solution or suspension.
- Suspending agents may also be included in tablets, which may include binders and lubricants in a suspension. Flavoring, preserving, suspending, thickening, or emulsifying agents may be also included to modify the taste and texture of the composition.
- the tablets and granules provided for oral administration may further be coated for ease of digestion.
- the extract containing dietary supplement composition may be combined with one or more other active agents.
- An active agent optionally functions synergistically with an extract material.
- Active agents illustratively include vitamins (such as vitamin A, vitamin B, vitamin C, vitamin D, vitamin E or vitamin K), antioxidants (such as acai, wolfberry, alpha lipoic acid, astazanthin, or fucoxanthin), or other regulators of one or more circadian rhythm protein (illustratively resveratrol or polygonum), or any combination of the above.
- the extract according to the present invention is available as a food additive thereto. Examples include foods in a liquid, semi-liquid, solid, paste, or jelly form.
- a subject is defined as an organism (such as a human, non- human primate, equine, bovine, murine, or other mammal), or a cell.
- a cell include neuronal cells, muscle cells, or any other cell that endogenously or exogenously expresses a circadian rhythm protein.
- Circadian rhythm protein expression is altered when a cell is contacted by an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof.
- proteins include the proteins CLOCK, BMAL1, FBXL3. FBX121, SIRT1.
- the Circadian Locomotor Output Cycles Kaput (CLOCK) protein is optionally altered in one or more expression characteristics in aspects of the invention.
- CLOCK protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes.
- an extract is an extract of rosemary that increases expression of a CLOCK protein.
- an extract is an extract of hemerocallis fulva that increases expression of a CLOCK protein.
- Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of CLOCK protein within 2 hours of administration.
- CLOCK protein expression is enhanced (e.g.
- CLOCK protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- BMAL1 Brain and muscle Arnt-like protein-1
- MOP3 a transcription factor known to regulate circadian rhythm.
- BMAL1 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes.
- an extract is an extract of rosemary that increases expression of a BMAL1 protein.
- an extract is an extract of hemerocallis fulva that increases expression of a BMAL1 protein.
- Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of BMAL1 protein within 2 hours of administration.
- BMAL1 protein expression is enhanced (e.g.
- BMAL1 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- F-box/LRR-repeat protein 3 is a member of the F-box protein family that functions in phosphorylation-dependent ubiquitination.
- FBXL3 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes.
- an extract is an extract of rosemary that increases expression of a FBXL3 protein.
- an extract is an extract of hemerocallis fulva that increases expression of a FBXL3 protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of FBXL3 protein within 2 hours of administration.
- FBXL3 protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween.
- FBXL3 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- F-box/LRR-repeat protein 21 is a member of the F-box protein family that functions in phosphorylation-dependent ubiquitination.
- FBXL21 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes.
- an extract is an extract of rosemary that increases expression of a FBXL21 protein.
- an extract is an extract of hemerocallis fulva that increases expression of a FBXL21 protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of FBXL21 protein within 2 hours of administration.
- FBXL21 protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween.
- FBXL21 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- SIRTl silicious mating type information regulation 2 homolog 1
- SIRTl protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes.
- an extract is an extract of rosemary that increases expression of a SIRTl protein.
- an extract is an extract of hemerocallis fulva that increases expression of a SIRTl protein.
- Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of SIRTl protein within 2 hours of administration.
- SIRTl protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween.
- SIRTl protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- circadian protein expression is detected and optionally quantified by enzyme linked immunosorbent assay (ELISA), mass spectrometry, western blot, gel electrophoresis optionally coupled with staining such as by Coomassie brilliant blue or silver stain, or by target specific stains, flow cytometry, immunoprecipitation, or by other method known in the art.
- ELISA enzyme linked immunosorbent assay
- mass spectrometry mass spectrometry
- western blot gel electrophoresis optionally coupled with staining such as by Coomassie brilliant blue or silver stain, or by target specific stains, flow cytometry, immunoprecipitation, or by other method known in the art.
- an ELISA is used to detect and optionally quantify circadian protein expression.
- ELISA kits for SIRTl and SIRT2 are available from Enzo Lifesciences, Plymouth Meeting, PA. Kits for other sirtuins are similarly available from commercial sources.
- Antibodies directed to CLOCK, BMAL1, and SIRT proteins suitable for use in ELISA, western blot, immunofluorescence or other applications are available from Santa Cruz Biotechnology, Santa Cruz, CA.
- Anti-FBXL21 and anti-FBXL3 antibodies are available from abeam, Cambridge, MA.
- a process optionally includes administration of an extract or dietary supplement containing extract at an administration time.
- Administration is optionally once daily, twice daily or more.
- Administration optionally is done 1, 2, 3, 4 or more times each day.
- administration is done on an as needed basis.
- administration is done once or twice weekly such as when a subject is transitioning from one schedule to another such as due to travel, shift work, weekend to work schedule or work to weekend schedule, or other necessary time.
- an administration time is following exercise.
- an administration time when one or more symptoms of a disease or condition are present, or conditions exist that such a symptom is expected or may occur.
- administration is prior to, following, during, or in lieu of a meal, snack or other consumption of food or nutritious drink.
- administration is prior to, during or following the consumption of alcohol.
- an administration time is at the initiation of a work period.
- Administration time is optionally from -4 hours to 12 hours following light exposure.
- administration is from 0 to 12 hours after light exposure.
- an administration time is upon waking independent of the time of day or the onset of light exposure.
- an administration time is in the evening.
- An administration time may be tailored to a desired time to have expression of such a protein or collection of proteins expressed to adjust the sleep-wake cycle of a subject, or to improve wakefulness at a desired time with the improvement in wakefulness optionally, not due to improved rest.
- the extract materials are taken orally between one and three times daily, or on an as needed basis; although, other routes of administration may be utilized.
- the extracts of the present invention may be utilized in the form of derivatives.
- the extracts may be bonded, chemically or physically, to other species and moieties such as synthetic polymers, liposomes, small organic molecules, chitin, chitosan, other biopolymers and the like.
- a subject is administered a composition in a dosage so that each dose of the extract supplement selected to deliver an amount of active agent suitable to have an effect on an expression characteristic of a circadian protein.
- Variable dosing regimens are operative. While in some instances, a single dose treatment may be effective in producing therapeutic effects, in other instances a treatment period in the range of, for example, six weeks to three or six months or more may be utilized.
- the composition may be administered orally, parentally, or intravenously, intramuscularly, intraperitoneally, by transdermal injection, or by contact with a cell or tissue such as by immersion or other form of contact.
- Injectables may be prepared in conventional forms, either liquid solutions or suspensions, solid forms suitable for solution or prior to injection, or as suspension in liquid prior to injection or as emulsions.
- the dose of the composition may vary depending on the age, weight, general condition of the subject. For example, dosage is in the range of 1 -1,000 mg of equivalent of dry extract powder extract per day may be an effective range. In some aspects, a dosage is between 10 and 800 mg per day, optionally from 100 to 600 mg per day, optionally 200-400 mg per day, optionally 400 mg per day. Dosage is optionally 1, 2, 3, 4, or more times daily. Optionally, dosage is twice daily. Optionally, dosage is 200 mg twice daily.
- the extract may also comprise 0.01%- 100% of the dry weight of the composition.
- a dietary supplement composition may comprise 20%-50% of the dry weight of the extract composition.
- An "effective amount" is defined as that capable of altering one or more expression characteristics of a circadian protein or a gene encoding a circadian protein relative to a control.
- An extract optionally is or is a part of a dietary supplement composition.
- An extract is optionally present in a dietary supplement composition at 10%- 100% by weight, optionally 20%-50% by weight, optionally 30%-40% by weight, or any value or range between 10% and 100% of the dry weight of the dietary supplement composition.
- the dried rosemary extract and Hemerocallis fulva extract were provided by Integrity Nutraceuticals International (Spring Hill, TN, USA).
- the dried powder of each extract contains 25% ursolic acid.
- the dried rosemary or Hemerocallis fulva powder (lg) was incubated with an aqueous phosphate buffer solution 0.01 M, H 7.4 (5mL), at 60°C for 4 hours, then centrifuged at 6000 rpm for 15 minutes. The supernatant was filtrated by 40 ⁇ filter mesh and saved for the concentration evaluation. Aliquots of RME and HFE were prepared at 10 mg/mL and stored at -20°C for use in subsequent studies.
- C6 glioma cells were purchased from American Type Culture Collection (ATCC; Manassas, VA). Cell cultures were grown in F-12 K medium (Gibco/Invitrogen) supplemented with 10% horse serum and 2% fetal bovine serum and maintained at 37 °C with 5% C02/95% air. Cultures were grown to 85% confluency in 75 mm flasks and, after trypsinization, were seeded in 35 mm culture dishes or 6 well plates; and grown to confluence during the experimental period. All cultures were used in the experiments between passages 22 and 32. Plated cells were grown for 2 days before treatment with an extract or control.
- IPEC-1 cells were carried out at 37°C in an atmosphere containing 5% CO2. Undifferentiated IPEC-1 cells were maintained in serial passage in growth medium (GM): DMEM/F12 medium supplemented with 5% FBS, insulin, transferrin (ITS Premix), epidermal growth factor, penicillin and streptomycin. Cells were maintained in serum-containing GM for 48 h for the experiments.
- GM growth medium
- the cells were stained with the primary antibody for the target of interest followed by incubation with AlexaFluor® 594-conjugated normal rabbit IgG (green) or AlexaFluor® 488-conjugated normal mouse IgG (red).
- C6 cells were treated with saline with or without RME (20, 50 and 100 ⁇ g/mL) or without HFE (50, 100 and 200 ⁇ g/mL) in the medium for 2h at 37°C.
- RME rosemary extract
- HFE hemerocallis fulva extract
- CLOCK circadian locomoter output cycles protein kaput
- IPEC-1 cells were treated with saline with or without RME (20, 50 and ⁇ ) or with or without HFE (50, 100 and 200 ⁇ ) in the medium for 6h at 37°C. 6h RME and HFE treatment significantly induced the intensity of immunofluorescence of CLOCK compared with the controls.
- FIG. 1 illustrates the effects of RME and HFE on CLOCK (FIG. 1A) and BMAL1 (FIG. IB) protein expression in C6 cells.
- C6 cells were treated with saline with or without RME (20 and 50 ⁇ g/mL) or with or without HFE (50 and 100 ⁇ g/mL) in the medium for 7h at 37°C. Representative immunoblots show increased expression in RME and HFE treated C6 cells.
- Oxygen glucose deprivation was induced in cultures as described by Panickar et al. (Panickar et al., 2009a). Briefly, cultures were washed twice with a balanced salt solution (BSS) with the following composition (in mM): NaCl 116, KC1 5.4, CaCl 2 1.8, MgS0 4 0.8, NaH 2 P0 4 0.83, NaHCOs 24 and phenol red 0.001w/v; pH 7.4.
- BSS balanced salt solution
- BSS was added to the cultures and placed in an airtight container (Billups chamber; Billups-Rothenberg Inc., Del Mar, CA) and continuously flushed with 95% N 2 /5% C0 2 for 5 hr. Following the OGD, BSS was removed and normal media was added immediately afterwards.
- Oxygen-glucose deprivation (OGD)-induced decreased CLOCK expression is reversed and further enhanced by RME and HFE in IPEC-1 cells.
- the RME and HFE were added to the media during 4hr OGD and added to normal media for other 3hr, immediately after the end of 4hr OGD at 37°C.
- Sample photomicrographs of CLOCK fluorescence after 4hr OGD and 3h reperfusion in normal control (CON), OGD, and OGD + two dosages RME or HFE 100 ⁇ g/ml or 200 ⁇ g/ml illustrate increases in CLOCK expression relative to control and OGD treated cells.
- FIG. 2 illustrates RME increased BMAL1 (A) and FBXL21 (B) protein levels in 4hr oxygen-glucose deprivation (OGD) and 2hr reperfusion treated C6 cells.
- the RME was added to the media during 4hr OGD and added to normal media for other 2hr, immediately after the end of 4hr OGD at 37°C.
- the blot bands are detected by Odyssey® Western Blotting.
- the blot was probed with rabbit anti-BMALl or mouse anti-FBX121 followed by detection with IRDye® 800CW Goat anti-Rabbit IgG (LI-COR P/N 926-32231) or IRDye 680RD Goat anti- Mouse IgG (LI-COR P/N 926-68070).
- IRDye® 800CW Goat anti-Rabbit IgG LI-COR P/N 926-32231
- IRDye 680RD Goat anti- Mouse IgG LI-COR P/N 926-68070.
- RME or HFE The effects of RME or HFE on SIRT1 protein expression in 4hr oxygen-glucose deprivation (OGD) and 2hr reperfusion treated C6 cells were examined by immunofluorescence.
- the RME or HFE were added to the media during 4hr OGD and added to normal media for other 2hr, immediately after the end of OGD at 37°C.
- SIRT1 fluorescence was increased in RME and HFE at either 50 ⁇ g/ml or 100 ⁇ g/ml in 4hr OGD and 2hr reperfusion treated C6 cells.
- Rat L-6 myogenic cell line (ATCC) were grown as a monolayer in DMEM with 10% fetal bovine serum (FBS) at 37°C in a humidified incubator with 5% C0 2 .
- L-6 cells (0.5xl0 6 ) were seeded on 6-well plates. Experiments were initiated 48 hr after plating.
- OGD oxygen-glucose deprivation
- the culture media was replaced with hypoglycemic media and placed in an airtight Billups chamber and flushed with 95%N2/5%C02 for 4 hr.
- hypoglycemic media was replaced with regular media and returned to the incubator, with or without RME, HFE or the mixture of RME/HFE for 20hr.
- the cells were washed twice with cold PBS, and harvested by scraping in 200 ⁇ of lysis buffer. Eighty micrograms of protein, which was determined by Bradford assay (Bio-Rad protein assay kit) was separated electrophoretically using a 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gel and transferred to a nitrocellulose membrane.
- the membrane was incubated at room temperature in Odyssey blocking buffer including 0.05% Tween-20 containing primary antibodies as above directed to one of the following: SIRT 1 (1 :500), CLOCK (1 :2000), Bmall (1 : 1000), or ⁇ -actin (1 : 1000). After washing with TBS-T three times, the membrane was incubated with anti -mouse or rabbit IRDye secondary antibodies (1 : 10,000) for 1 h at room temperature. Quantitative IR western blot detection was performed with Odyssey CLx Imager. Data were analyzed by one-way analysis of variance followed by post-hoc analysis of between group mean differences by Fisher's Least Significant Difference (LSD) test. Different superscripts indicate significant differences among groups (p ⁇ 0.05).
- LSD Least Significant Difference
- SIRT1 levels are increased in OGD treated L-6 cells by RME and/or HFE.
- the quantified amounts of protein are illustrated in FIG. 3B demonstrating significantly increased amounts of SIRT1 levels relative to control.
- An additional effect is observed in RME+HFE mixture treated cells on SIRT1 expression, compared with individual RME or HFE only treated cells.
- FIG. 4 illustrates CLOCK protein levels increased in OGD treated L-6 cells by RME and/or HFE.
- RME, HFE, or both significantly enhance CLOCK protein expression in OGD treated L6 skeletal muscle cells.
- An additional effect in RME+HFE mixture treated cells on CLOCK expression is also observed compared to individual RME or HFE only treated cells.
- FIG. 5 illustrates Bmall protein levels increased in OGD treated L-6 cells by RME and/or HFE.
- RME, HFE, or both significantly enhance Bmall protein expression in OGD treated L-6 skeletal muscle cells.
- An additional effect is observed in cells treated with the RME+HFE compared with individual RME or HFE only treated cells.
- Ursolic acid enhances the expression of circadian rhythm proteins
- iPEC-1 cells were grown as a monolayer in DMEM with 10% fetal bovine serum (FBS) and the necessary supplements at 37°C in a humidified incubator with 5% CO2. iPECl cells were seeded on 35 mm dishes. Experiments were initiated 48 hr after plating. Cells were treated with saline or with ursolic acid at three separate dosages (1 ⁇ ; 5 ⁇ ; or 20 ⁇ ) in the medium for 24 hr at 37°C. The cells were then washed with ice-cold PBS and fixed with 4% paraformaldehyde for 10 min at room temperature followed by permeabilization with 0.3% Triton X-100 for 10 min.
- FBS fetal bovine serum
- Immunological methods e.g., preparation of antigen- specific antibodies, immunoprecipitation, and immunoblotting are described, e.g., in Current Protocols in Immunology, ed. Coligan et al., John Wiley & Sons, New York, 1991 ; and Methods of Immunological Analysis, ed. Masseyeff et al., John Wiley & Sons, New York, 1992.
- Shaw E Toiler GH: Circadian rhythm and cardiovascular disease. Curr.Atheroscler.Rep.
- Patents, publications, and applications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents, publications, and applications are incorporated herein by reference to the same extent as if each individual patent, publication, or application was specifically and individually incorporated herein by reference.
Abstract
Provided are process of regulating expression of one or more genes or proteins involved in circadian rhythm. A subject such as a cell is administered or contacted to an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof, optionally provided as a component of a dietary supplement. The presence of one or more active agents in the extracts administered at a targeted administration time alters the expression of one or more genes or proteins involved in circadian rhythm, illustratively CLOCK, BMAL1, FBXL3, FBXL21, or SIRT1.
Description
EXTRACTS OF ROSEMARY OR HEMEROCALLIS FULVA AND METHODS OF USING SAME TO PROMOTE CIRCADIAN RHYTHM
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application depends from and claims priority to U.S. Provisional Application No: 61/903,434 filed November 13, 2013, and U.S. Provisional Application No: 61/903,440 filed November 13, 2013, the entire contents of each of which are incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to dietary supplement compositions containing rosemary or Hemerocallis fulva extracts and methods for promoting or maintaining or modulating protein expression or circadian rhythm.
BACKGROUND OF THE INVENTION
[0003] Living organisms from cyanobacteria to mammals display circadian rhythms (i.e., oscillations with 24-h periodicities) in multiple physiological and behavioral processes. These rhythms are found in nearly all living organisms. Circadian rhythms are generated endogenously and function under tightly regulated genetic control.
[0004] Circadian rhythms control a variety of biological processes, including sleep/wake cycles, body temperature, hormone secretion, gastrointestinal function, metabolic glucose homeostasis, and immunological functions. Biological clocks exhibiting circadian rhythms exist in virtually all tissues, with a series of clock genes generating the rhythm through protein feedback effects on their own synthesis.
[0005] These multiple endogenous clocks are distributed in every cell of the organism, which may result in each organ having its own timed circadian rhythm. A complex mechanism of activation and feedback regulate the expression, post-translational modification, translocation, and degradation of circadian proteins. The transcription factor CLOCK-BMAL1 is a core component of the molecular clock machinery that drives circadian gene expression and physiology in mammals. CLOCK and BMALl are each basic helix-loop-helix (bHLH) PAS- domain transcription factors that together form the positive elements of the central oscillatory loop. CLOCK and BMALl form a heterodimer that binds to E-box elements in the promoters of target genes. Some of the primary genes under transcriptional control by CLOCK:BMALl
encode the three Period (mPerl, mPer2, and mPer3) proteins and two Cryptochromegenes (mCryl and mCryl) proteins. Following translation of the Per and Cry proteins, they translocate to the nucleus where they act as potent inhibitors of CLOCK:BMALl -induced gene transcription forming a negative feedback loop and regulating the rhythmic expression of many genes. The PERIOD protein mPER2, the gene of which is also under CLOCK:BMALl transcriptional control, functions as a stimulator of Bmal 1 transcription, forming the positive feedback loop and enhancing CLOCK:BMALl activity. The regulation of these positive and negative feedback loops regulates the circadian rhythm within the cell.
[0006] SIRT1, a nicotinamide adenine dinucleotide-dependent sirtuin, has been shown to promote cell survival by inhibiting apoptosis or cellular senescence in mammalian cells. Recent studies have provided a link between the cellular metabolic function of SIRT1 and the circadian rhythm (controlled by the CLOCK:BMALl machinery) where it has been shown that SIRT1 controls circadian clock circuitry and promotes cell survival providing a connection with age- related neoplasms. Also, circadian function decays with aging in normal mice, and boosting their SIRTl levels in the brain could prevent this decay. Conversely, loss of SIRT1 function impairs circadian control in young mice, mimicking what happens in normal aging. Moreover, SIRTl has been shown to exert this control by regulating the genes BMAL1 and CLOCK, the two major keepers of the central circadian clock.
[0007] Oxygen and circadian rhythmicity are essential in a myriad of physiological processes to maintain homeostasis, from blood pressure and sleep/wake cycles, as well as in cellular signaling pathways that play critical roles in health and disease. Oxidative stress can induce the dysregulated circadian rhythms. Thus, there is a need for new compositions and methods for regulating proper protein expression and circadian rhythm.
SUMMARY OF THE INVENTION
[0008] The following summary of the invention is provided to facilitate an understanding of some of the innovative features unique to the present invention and is not intended to be a full description. A full appreciation of the various aspects of the invention can be gained by taking the entire specification, claims, drawings, and abstract as a whole.
[0009] Stresses can have a detrimental effect on many physiological regulatory systems. Among these are circadian rhythms. It was discovered that particular extracts of rosemary, hemerocallis fulva, the active portions or components thereof, or combinations thereof can
restore expression of mediators of circadian rhythms in cells such as the proteins CLOCK, BMALl, FBXL3, FBXL21, or SIRTl . This can beneficially effect physiological function and reduce the negative effects of stresses.
[0010] Provided are processes of altering an expression characteristic of a CLOCK, BMALl, FBXL3, FBXL21, or SIRTl protein in a subject including: administering to said subject an effective amount of an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof at an administration time, said effective amount comprising ursolic acid at 10% or greater by weight; where the administering occurs at or between -4 hours to 12 hours after light exposure. In some aspects, the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10- 14 hours after light exposure, optionally at or between -4 hours to 0 hours prior to light exposure.
[0011] Provided are processes of altering an expression characteristic of a circadian rhythm protein in a subject including administering to said subject an effective amount of an extract of rosemary, an extract of hemerocallis fulva, an active portion or component thereof, or combinations thereof at an administration time, where the administration time occurs such that the extract, an active portion or component thereof, or combinations thereof contacts a cell having a circadian rhythm thereby increasing the expression of CLOCK, BMALl, FBXL3, FBXL21, SIRTl, or combinations thereof in said cell.
[0012] In some aspects, an extract is a water extract. In some aspects, an extract is a component of a dietary supplement.
[0013] Administration is optionally once daily, twice daily, more frequently, or on an as needed basis. Administration optionally occurs at or between -4 hours to 12 hours after light exposure. In some aspects, the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10-14 hours after light exposure, optionally at or between -4 hours to 0 hours prior to light exposure.
[0014] An extract in any of the processes optionally includes 10% or greater ursolic acid, optionally 25% or greater ursolic acid.
[0015] Also provided are processes of altering an expression characteristic of a circadian rhythm protein in a subject including administering to a subject, where the administration time occurs such that said ursolic acid contacts a cell having a circadian rhythm thereby increasing the expression of CLOCK, BMALl, FBXL3, FBXL21, SIRTl, or combinations thereof in said subject. The ursolic acid is optionally obtained from extracting the ursolic acid from rosemary,
hemerocallis fulva, or combinations thereof with water, an alcohol or combinations thereof. The ursolic acid is optionally administered once daily, twice daily, more frequently, or on an as needed basis. Administration optionally occurs at or between -4 hours to 12 hours after light exposure. In some aspects, the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10-14 hours after light exposure, optionally at or between -4 hours to 0 hours prior to light exposure.
[0016] In any of the processes a subject is optionally in need of improved expression of a circadian rhythm gene or protein, optionally due to exposure to a stress or other environmental condition that reduces expression of a circadian rhythm gene or protein such as CLOCK, BMAL1, FBXL3, FBXL21, SIRT1, or combinations thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] FIG. 1 A illustrates the effects of RME and HFE on CLOCK protein expression in C6 cells;
[0018] FIG. IB illustrates the effects of RME and HFE on CLOCK protein expression in C6 cells;
[0019] FIG. 2A illustrates RME increased BMAL1 protein levels in 4hr oxygen-glucose deprivation (OGD) and 2hr reperfusion treated C6 cells;
[0020] FIG. 2B illustrates RME increased FBXL21 protein levels in 4hr oxygen-glucose deprivation (OGD) and 2hr reperfusion treated C6 cells;
[0021] FIG. 3 A illustrates SIRT1 levels increased in OGD Rat L-6 cells treated with RME, HFE, or both;
[0022] FIG. 3B illustrates quantifiable increases in SIRTl levels in OGD treated Rat L-6 cells;
[0023] FIG. 4A illustrates CLOCK protein levels increased in OGD Rat L-6 cells treated with RME, HFE, or both;
[0024] FIG. 4B illustrates quantifiable increases in CLOCK levels in OGD treated Rat L-6 cells by RME, HFE, or both;
[0025] FIG. 5 A illustrates Bmall protein levels increased in OGD Rat L-6 cells treated with RME, HFE, or both;
[0026] FIG. 5B illustrates quantifiable increases in Bmall levels in OGD treated Rat L-6 cells by RME, HFE, or both;
DETAILED DESCRIPTION OF ASPECTS OF THE INVENTION
[0027] The following description of particular aspect(s) is merely exemplary in nature and is in no way intended to limit the scope of the invention, its application, or uses, which may, of course, vary. The invention is described with relation to the non-limiting definitions and terminology included herein. These definitions and terminology are not designed to function as a limitation on the scope or practice of the invention but are presented for illustrative and descriptive purposes only. While the processes or compositions are described as an order of individual steps or using specific materials, it is appreciated that steps or materials may be interchangeable such that the description of the invention may include multiple parts or steps arranged in many ways as is readily appreciated by one of skill in the art.
[0028] Provided are processes for altering a circadian rhythm in a subject. Altering a circadian rhythm is understood as altering, optionally increasing, the expression level, post- translational modification state, nuclear or cytoplasmic location or translocation, or RNA expression rate of a protein normally involved in a 24-hour or other regular cycle in one or more cell types in a subject. A process includes administering to a subject an effective amount of an extract of rosemary (RME), an extract of hemerocallis fulva (HFE), active portion or component thereof, or combinations thereof or a dietary supplement containing in whole or in part of an extract of rosemary, an extract of hemerocallis fulva, active portion or component thereof, or combinations thereof. Such an administration is at an administration time. The administration of the extract of rosemary, an extract of hemerocallis fulva, active portion thereof, or combinations thereof or a dietary supplement containing such will alter an expression characteristic of a protein of CLOCK, BMAL1, FBXL3, FBX121, SIRT1, or combinations thereof in the subject. As such, the invention has utility for altering or adjusting one or more expression characteristics of a protein involved in a circadian rhythm in a cell.
[0029] An "expression characteristic" is the transcription of a gene encoding a circadian rhythm protein, translation of RNA encoding a circadian rhythm protein, localization of RNA encoding a circadian rhythm protein, protein function, protein localization, protein post- translational modification, or other parameter recognized in the art related to protein expression and function.
[0030] The invention provides materials in the form of botanical extracts, such as an extract of rosemary, an extract of hemerocallis fulva, active portion thereof, or combinations thereof, alone or as part of a dietary supplement that have utility for altering one or more expression
characteristics of a protein involved in a circadian rhythm in a subject. The extract, active portion thereof, or dietary supplement may be in pharmaceutical dietary supplement composition in solid, semi-solid, or liquid dosage forms, such as, for example, tablets, chewables, suppositories, pills, capsules, powders, liquids, or suspensions, and may be provided in unit dosages suitable for a single administration. Time release preparations are also contemplated as effective dosage formulations. The compositions may include an effective amount of a selected extract of rosemary, hemerocallis fulva, active portion thereof, or combinations, optionally in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, or diluents.
[0031] The extracts are recognized to include an active ingredient as an active portion of an extract, or the sole portion of an extract. "Active ingredient" refers a component present in the extract that renders, directly or indirectly, the intended effect of the extract. In some aspects, an active ingredient is ursolic acid. Extraction parameters such as water quality, heating temperature, drying temperature, heating time, drying time, and filtering processes all contribute to the quality and efficiency of the process. Water quality directly affects the concentration of active ingredient(s). Poor quality water may cause active ingredient(s) to become decomposed or oxidized during or following the extraction process.
[0032] The rosemary or hemerocallis fulva may be obtained from various resources. Rosemary, or Rosmarinus officinalis, is a woody bush native to the Mediterranean region. Extracts of rosemary may be made from Rosmarinus spp. and preferably from the leaves and young flowering tops of fresh rosemary (Rosmarinus officinalis L. and its cultivars). Rosemary extraction may be performed by harvesting the leaves of a rosemary plant and reducing them in size such as by chopping to improve solvent penetration. A typical particle size is optionally 0.5 - 5.0 mm, or any value or range therebetween. In some aspects, the leaf is chopped into a powder type substance with a particle size of less than 0.5 mm. The chopped plant material is combined with a suitable extraction solvent such as water and/or a low molecular weight alcohol (e.g. C4- Ce alcohol) such as ethanol. The plant material is combined with the solvent for an extraction time of 18 to 36 hours. The extraction temperature is optionally the range 10°C to 45°C. The resulting extract liquid is separated from the solid material and filtered, optionally with a sterile filter. Optionally, the resulting extract is poured onto nonstick tray and allowed to dry at 80- 90°C. Vacuum-spray dry equipment is optionally used for the drying procedure. The resulting dry extract powder is weighed. An extraction ratio is calculated as w/20 xl00% with w as the
weight (g) of the dry extract powder. The sample and water ratio, heat time, volume of water in the second extraction may vary depending on the amount of the raw material used for extraction.
[0033] Extracts of Hemerocallis fulva are optionally obtained from extraction in an extraction solvent such as water and/or low molecular weight alcohol such as ethanol. Extracts are prepared from plants belonging to the genus Hemerocallis of the family Liliaceae of the order Liliales are used. Examples of such plants include Akinowasuregusa {Homerocallis fulva L. sempervirens M. Hotta or Homerocallis sempervirens Araki), Honkanzo (Hemerocallis fulva L. var. fulva), Nokanzo (Hemerocallis fulva L. var. longituba Maxim or Hemerocallis longituba Miq.), and Yabukanzo (Hemerocallis fulva L. var. kwanso Regal), An extract is optionally prepared from whole plants or plant parts, such as leaves, stems, and roots.
[0034] In some aspects, an extract is prepared by drying the plant material and optionally cutting the material into a suitable size for extraction, such as the sizes described for rosemary. The plant material is combined with an extraction solvent (e.g. water, aqueous buffer, low molecular weight alcohol, or combinations thereof) that is preheated to a temperature of 60°C to 100°C for an extraction time, typically of 20 to 90 minutes. The particulate material is then removed by gravity separation, centrifugatkm, or filtering, optionally with a filter size suitable for aseptic filtration. The resulting extract is optionally poured onto nonstick tray and allowed to dry at 80-90°C. Vacuum-spray dry equipment is optionally used for the drying procedure. The resulting dry extract powder is weighed. An extraction ratio is calculated as w/20 xl00% with w as the weight (g) of the dry extract powder. The sample and water ratio, heat time, volume of water in the extraction may vary depending on the amount of the raw material used for extraction.
[0035] In some aspects, a second extraction of either plant material is performed optionally using the same extraction parameters or differing extraction parameters. Optionally, a second extraction is performed in a low molecular weight alcohol optionally of C2-C4. The first and second extraction solutions are optionally combined together and dried.
[0036] In some aspects, an extract includes or consists of ursolic acid as an active ingredient. Ursolic acid is optionally present in an extract at a concentration of 10 weight percent or greater. In some aspects, ursolic acid is present in an extract at a concentration of 25 weight percent or greater. Optionally, ursolic acid is present at a weight percent at or in excess of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, or 99.9.
[0037] While ursolic acid is descried as a component of or the product representing an extract, it is appreciated that the term "extract" may in some aspects include otherwise isolated, purified, or chemically synthesized ursolic acid. As such, an "extract" is in some aspects ursolic acid obtained either by extraction from a natural or non-natural source, or used as a chemically synthesized ursolic acid.
[0038] Depending on the intended mode of administration, the extract can be in pharmaceutical compositions in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, or suspensions, and may be provided in unit dosages suitable for a single administration. Time release preparations are specifically contemplated as effective dosage formulations. The compositions will include an effective amount of the selected extract in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, or diluents.
[0039] In a solid composition aspect, conventional nontoxic solid carriers may include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talc, cellulose, glucose, sucrose and magnesium carbonate. Liquid pharmaceutically administrable compositions may, for example, be prepared by dissolving or dispersing an active compound with optimal pharmaceutical adjuvants in an excipient, such as water, saline, aqueous dextrose, glycerol, or ethanol, to form a solution or suspension. For example, the pharmaceutical composition may contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, for example, sodium acetate or triethanolamine oleate. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's The Science and Practice of Pharmacy (20th Edition).
[0040] In oral administration aspects, fine powders or granules of extract, or a liquid extract may contain diluting, dispersing, or surface active agents. The extract may be presented in water or in syrup, in capsules or sachets in the dry state, or in a non-aqueous solution or suspension. Suspending agents may also be included in tablets, which may include binders and lubricants in a suspension. Flavoring, preserving, suspending, thickening, or emulsifying agents may be also included to modify the taste and texture of the composition. The tablets and granules provided for oral administration may further be coated for ease of digestion.
[0041] In some aspects, the extract containing dietary supplement composition may be combined with one or more other active agents. An active agent optionally functions
synergistically with an extract material. Active agents illustratively include vitamins (such as vitamin A, vitamin B, vitamin C, vitamin D, vitamin E or vitamin K), antioxidants (such as acai, wolfberry, alpha lipoic acid, astazanthin, or fucoxanthin), or other regulators of one or more circadian rhythm protein (illustratively resveratrol or polygonum), or any combination of the above. The extract according to the present invention is available as a food additive thereto. Examples include foods in a liquid, semi-liquid, solid, paste, or jelly form.
[0042] Processes are provided for altering an expression characteristic of a circadian rhythm protein in a subject. As used herein, a subject is defined as an organism (such as a human, non- human primate, equine, bovine, murine, or other mammal), or a cell. Illustrative examples of cells include neuronal cells, muscle cells, or any other cell that endogenously or exogenously expresses a circadian rhythm protein.
[0043] The inventors unexpectedly discovered that administration of an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof will alter one or more expression characteristics of a circadian rhythm protein. Circadian rhythm protein expression is altered when a cell is contacted by an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof. Illustrative examples of proteins include the proteins CLOCK, BMAL1, FBXL3. FBX121, SIRT1.
[0044] The Circadian Locomotor Output Cycles Kaput (CLOCK) protein is optionally altered in one or more expression characteristics in aspects of the invention. Optionally CLOCK protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes. Optionally, an extract is an extract of rosemary that increases expression of a CLOCK protein. Optionally, an extract is an extract of hemerocallis fulva that increases expression of a CLOCK protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of CLOCK protein within 2 hours of administration. Illustratively, CLOCK protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween. Optionally, CLOCK protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
[0045] Brain and muscle Arnt-like protein-1 (BMAL1; also known as MOP3 or Arnt3) is a transcription factor known to regulate circadian rhythm. Optionally BMAL1 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive
processes. Optionally, an extract is an extract of rosemary that increases expression of a BMAL1 protein. Optionally, an extract is an extract of hemerocallis fulva that increases expression of a BMAL1 protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of BMAL1 protein within 2 hours of administration. Illustratively, BMAL1 protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween. Optionally, BMAL1 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
[0046] F-box/LRR-repeat protein 3 (FBXL3) is a member of the F-box protein family that functions in phosphorylation-dependent ubiquitination. Optionally FBXL3 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes. Optionally, an extract is an extract of rosemary that increases expression of a FBXL3 protein. Optionally, an extract is an extract of hemerocallis fulva that increases expression of a FBXL3 protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of FBXL3 protein within 2 hours of administration. Illustratively, FBXL3 protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween. Optionally, FBXL3 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
[0047] F-box/LRR-repeat protein 21 (FBXL21) is a member of the F-box protein family that functions in phosphorylation-dependent ubiquitination. Optionally FBXL21 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes. Optionally, an extract is an extract of rosemary that increases expression of a FBXL21 protein. Optionally, an extract is an extract of hemerocallis fulva that increases expression of a FBXL21 protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of FBXL21 protein within 2 hours of administration. Illustratively, FBXL21 protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween. Optionally, FBXL21 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
[0048] Sirtuin 1 (silent mating type information regulation 2 homolog 1) (SIRTl) is a protein involved in deacetylation of proteins that contribute to cellular regulation. Optionally SIRTl protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes. Optionally, an extract is an extract of rosemary that increases expression of a SIRTl protein. Optionally, an extract is an extract of hemerocallis fulva that increases expression of a SIRTl protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of SIRTl protein within 2 hours of administration. Illustratively, SIRTl protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween. Optionally, SIRTl protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
[0049] Detecting and optionally quantifying circadian protein expression is achieved by any of many methods known in the art. Illustratively, circadian protein expression is detected and optionally quantified by enzyme linked immunosorbent assay (ELISA), mass spectrometry, western blot, gel electrophoresis optionally coupled with staining such as by Coomassie brilliant blue or silver stain, or by target specific stains, flow cytometry, immunoprecipitation, or by other method known in the art. In some aspects, an ELISA is used to detect and optionally quantify circadian protein expression. For example, ELISA kits for SIRTl and SIRT2 are available from Enzo Lifesciences, Plymouth Meeting, PA. Kits for other sirtuins are similarly available from commercial sources. Antibodies directed to CLOCK, BMAL1, and SIRT proteins suitable for use in ELISA, western blot, immunofluorescence or other applications are available from Santa Cruz Biotechnology, Santa Cruz, CA. Anti-FBXL21 and anti-FBXL3 antibodies are available from abeam, Cambridge, MA.
[0050] A process optionally includes administration of an extract or dietary supplement containing extract at an administration time. Administration is optionally once daily, twice daily or more. Administration optionally is done 1, 2, 3, 4 or more times each day. Optionally, administration is done on an as needed basis. Optionally irregularly, or weekly. Optionally, administration is done once or twice weekly such as when a subject is transitioning from one schedule to another such as due to travel, shift work, weekend to work schedule or work to weekend schedule, or other necessary time. Optionally, an administration time is following exercise. Optionally, an administration time when one or more symptoms of a disease or
condition are present, or conditions exist that such a symptom is expected or may occur. Optionally, administration is prior to, following, during, or in lieu of a meal, snack or other consumption of food or nutritious drink. Optionally, administration is prior to, during or following the consumption of alcohol. Optionally, an administration time is at the initiation of a work period.
[0051] Administration time is optionally from -4 hours to 12 hours following light exposure. Optionally, administration is from 0 to 12 hours after light exposure. Optionally, an administration time is upon waking independent of the time of day or the onset of light exposure. Optionally, an administration time is in the evening. The inventors have shown that administration of an effective amount of an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof increases the expression of several proteins involved in several circadian processes. An administration time may be tailored to a desired time to have expression of such a protein or collection of proteins expressed to adjust the sleep-wake cycle of a subject, or to improve wakefulness at a desired time with the improvement in wakefulness optionally, not due to improved rest.
[0052] In a typical regimen, the extract materials are taken orally between one and three times daily, or on an as needed basis; although, other routes of administration may be utilized. Also, it should be noted that the extracts of the present invention may be utilized in the form of derivatives. For example, the extracts may be bonded, chemically or physically, to other species and moieties such as synthetic polymers, liposomes, small organic molecules, chitin, chitosan, other biopolymers and the like. In view of the teaching presented herein, still further combinations will be readily apparent to those of skill in the art.
[0053] A subject is administered a composition in a dosage so that each dose of the extract supplement selected to deliver an amount of active agent suitable to have an effect on an expression characteristic of a circadian protein. Variable dosing regimens are operative. While in some instances, a single dose treatment may be effective in producing therapeutic effects, in other instances a treatment period in the range of, for example, six weeks to three or six months or more may be utilized. The composition may be administered orally, parentally, or intravenously, intramuscularly, intraperitoneally, by transdermal injection, or by contact with a cell or tissue such as by immersion or other form of contact. Injectables may be prepared in conventional forms, either liquid solutions or suspensions, solid forms suitable for solution or prior to injection, or as suspension in liquid prior to injection or as emulsions.
[0054] The dose of the composition may vary depending on the age, weight, general condition of the subject. For example, dosage is in the range of 1 -1,000 mg of equivalent of dry extract powder extract per day may be an effective range. In some aspects, a dosage is between 10 and 800 mg per day, optionally from 100 to 600 mg per day, optionally 200-400 mg per day, optionally 400 mg per day. Dosage is optionally 1, 2, 3, 4, or more times daily. Optionally, dosage is twice daily. Optionally, dosage is 200 mg twice daily. The extract may also comprise 0.01%- 100% of the dry weight of the composition. For example, a dietary supplement composition may comprise 20%-50% of the dry weight of the extract composition. An "effective amount" is defined as that capable of altering one or more expression characteristics of a circadian protein or a gene encoding a circadian protein relative to a control.
[0055] An extract optionally is or is a part of a dietary supplement composition. An extract is optionally present in a dietary supplement composition at 10%- 100% by weight, optionally 20%-50% by weight, optionally 30%-40% by weight, or any value or range between 10% and 100% of the dry weight of the dietary supplement composition.
[0056] Various aspects of the present invention are illustrated by the following non-limiting examples. The examples are for illustrative purposes and are not a limitation on any practice of the present invention. It will be understood that variations and modifications can be made without departing from the spirit and scope of the invention. EXPERIMENTAL
[0057] It was investigated whether an extract of rosemary (RME) and an extract of hemerocallis fulva (HFE) regulate key circadian protein expression in normal rat C6 glioma cells and IPEC-1 (Porcine intestinal epithelial cell lines), using immunofluorescence and western blotting analyses. Oxygen and circadian rhythmicity are essential in a myriad of physiological processes to maintain homeostasis, from blood pressure and sleep/wake cycles, down to cellular signaling pathways that play critical roles in health and disease. Oxidative stress can induce the dysregulated circadian rhythms. We also test if RME and HFE attenuate the damages of these proteins expression from oxygen-glucose deprivation (OGD).
[0058] The dried rosemary extract and Hemerocallis fulva extract were provided by Integrity Nutraceuticals International (Spring Hill, TN, USA). The dried powder of each extract contains 25% ursolic acid. To obtain a more pure extract fraction, the dried rosemary or Hemerocallis fulva powder (lg) was incubated with an aqueous phosphate buffer solution 0.01
M, H 7.4 (5mL), at 60°C for 4 hours, then centrifuged at 6000 rpm for 15 minutes. The supernatant was filtrated by 40 μιη filter mesh and saved for the concentration evaluation. Aliquots of RME and HFE were prepared at 10 mg/mL and stored at -20°C for use in subsequent studies.
[0059] C6 glioma cells (CCL-107) were purchased from American Type Culture Collection (ATCC; Manassas, VA). Cell cultures were grown in F-12 K medium (Gibco/Invitrogen) supplemented with 10% horse serum and 2% fetal bovine serum and maintained at 37 °C with 5% C02/95% air. Cultures were grown to 85% confluency in 75 mm flasks and, after trypsinization, were seeded in 35 mm culture dishes or 6 well plates; and grown to confluence during the experimental period. All cultures were used in the experiments between passages 22 and 32. Plated cells were grown for 2 days before treatment with an extract or control.
[0060] Culture of IPEC-1 cells was carried out at 37°C in an atmosphere containing 5% CO2. Undifferentiated IPEC-1 cells were maintained in serial passage in growth medium (GM): DMEM/F12 medium supplemented with 5% FBS, insulin, transferrin (ITS Premix), epidermal growth factor, penicillin and streptomycin. Cells were maintained in serum-containing GM for 48 h for the experiments.
[0061] The effects of the RME or HFE were studied in cells by staining for target proteins using the following primary antibodies all provided by Abeam Inc, Cambridge, MA. SIRT 1 was detected by abl 10304 Mouse monoclonal [19A7AB4]. KAT13D / CLOCK was detected using abl34165 Rabbit monoclonal [EPR6227]. BMAL1 was detected using the C-terminal recognizing antibody abl40646 Rabbit monoclonal [EPR8355(2)]. FBXL3 was detected using ab96645 Rabbit polyclonal. FBXL21 was detected using ab57302 Mouse monoclonal. For each immunofluorescence study the cells were stained with the primary antibody for the target of interest followed by incubation with AlexaFluor® 594-conjugated normal rabbit IgG (green) or AlexaFluor® 488-conjugated normal mouse IgG (red).
[0062] C6 cells were treated with saline with or without RME (20, 50 and 100μg/mL) or without HFE (50, 100 and 200μg/mL) in the medium for 2h at 37°C. The effects of rosemary extract (RME) and hemerocallis fulva extract (HFE) on circadian locomoter output cycles protein kaput (CLOCK) protein expression in C6 glioma cells are determined by immunofluorescence. A2h treatment with RME or HFE significantly induced increased the intensity of immunofluorescence of CLOCK compared with the controls indicating enhanced CLOCK protein expression.
[0063] Similar results of RME and HFE on CLOCK protein expression were observed in IPEC-1 cells. IPEC-1 cells were treated with saline with or without RME (20, 50 and ΙΟΟμ^ιηΕ) or with or without HFE (50, 100 and 200μ^ιηΕ) in the medium for 6h at 37°C. 6h RME and HFE treatment significantly induced the intensity of immunofluorescence of CLOCK compared with the controls.
[0064] FIG. 1 illustrates the effects of RME and HFE on CLOCK (FIG. 1A) and BMAL1 (FIG. IB) protein expression in C6 cells. C6 cells were treated with saline with or without RME (20 and 50 μg/mL) or with or without HFE (50 and 100 μg/mL) in the medium for 7h at 37°C. Representative immunoblots show increased expression in RME and HFE treated C6 cells.
[0065] Oxygen glucose deprivation (OGD) was induced in cultures as described by Panickar et al. (Panickar et al., 2009a). Briefly, cultures were washed twice with a balanced salt solution (BSS) with the following composition (in mM): NaCl 116, KC1 5.4, CaCl2 1.8, MgS04 0.8, NaH2P04 0.83, NaHCOs 24 and phenol red 0.001w/v; pH 7.4. Following washes, BSS was added to the cultures and placed in an airtight container (Billups chamber; Billups-Rothenberg Inc., Del Mar, CA) and continuously flushed with 95% N2/5% C02 for 5 hr. Following the OGD, BSS was removed and normal media was added immediately afterwards.
[0066] Oxygen-glucose deprivation (OGD)-induced decreased CLOCK expression is reversed and further enhanced by RME and HFE in IPEC-1 cells. The RME and HFE were added to the media during 4hr OGD and added to normal media for other 3hr, immediately after the end of 4hr OGD at 37°C. Sample photomicrographs of CLOCK fluorescence after 4hr OGD and 3h reperfusion in normal control (CON), OGD, and OGD + two dosages RME or HFE 100 μg/ml or 200 μg/ml illustrate increases in CLOCK expression relative to control and OGD treated cells.
[0067] Immunofluorescence measurements demonstrated that RME and HFE each increased FBXL3 protein levels in 4hr oxygen-glucose deprivation (OGD) and 2hr reperfusion treated C6 glioma cells. The RME or HFE were added to the media during 4hr OGD and added to normal media for other 2hr, immediately after the end of 4hr OGD at 37°C. Sample photomicrographs of FBXL3 fluorescence after 4hr OGD and 2h reperfusion in OGD, and OGD + two dosages RME and HFE 50 μg/ml or 100 μg/ml illustrate enhanced expression of FBXL3 due to the presence of the extract.
[0068] RME (A) and HFE (B) both increased FBXL3 protein levels in 4hr oxygen-glucose deprivation (OGD) and 2hr reperfusion treated IPEC-1 cells as illustrated by
immunofluorescence. The RME and HFE were added to the media during 4hr OGD and added to normal media for other 3hr, immediately after the end of 4hr OGD at 37°C. Sample photomicrographs of FBXL3 fluorescence after 4hr OGD and 3h reperfusion in OGD, and OGD + RME or HFE at either 50 μg/ml or 100 μg/ml demonstrate enhanced expression of FBXL3 protein due to extract exposure.
[0069] FIG. 2 illustrates RME increased BMAL1 (A) and FBXL21 (B) protein levels in 4hr oxygen-glucose deprivation (OGD) and 2hr reperfusion treated C6 cells. The RME was added to the media during 4hr OGD and added to normal media for other 2hr, immediately after the end of 4hr OGD at 37°C. The blot bands are detected by Odyssey® Western Blotting. Briefly, the blot was probed with rabbit anti-BMALl or mouse anti-FBX121 followed by detection with IRDye® 800CW Goat anti-Rabbit IgG (LI-COR P/N 926-32231) or IRDye 680RD Goat anti- Mouse IgG (LI-COR P/N 926-68070). Sample photomicrographs of FBXL21 fluorescence after 4hr OGD and 2h reperfusion in OGD, and OGD + two dosages RME are illustrated.
[0070] The effects of RME or HFE on SIRT1 protein expression in 4hr oxygen-glucose deprivation (OGD) and 2hr reperfusion treated C6 cells were examined by immunofluorescence. The RME or HFE were added to the media during 4hr OGD and added to normal media for other 2hr, immediately after the end of OGD at 37°C. SIRT1 fluorescence was increased in RME and HFE at either 50 μg/ml or 100 μg/ml in 4hr OGD and 2hr reperfusion treated C6 cells.
[0071] Rat L-6 myogenic cell line (ATCC) were grown as a monolayer in DMEM with 10% fetal bovine serum (FBS) at 37°C in a humidified incubator with 5% C02. L-6 cells (0.5xl06) were seeded on 6-well plates. Experiments were initiated 48 hr after plating. For oxygen-glucose deprivation (OGD) of the L-6 cells, the culture media was replaced with hypoglycemic media and placed in an airtight Billups chamber and flushed with 95%N2/5%C02 for 4 hr. Following OGD treatment, hypoglycemic media was replaced with regular media and returned to the incubator, with or without RME, HFE or the mixture of RME/HFE for 20hr. After treatment, the cells were washed twice with cold PBS, and harvested by scraping in 200 μΐ of lysis buffer. Eighty micrograms of protein, which was determined by Bradford assay (Bio-Rad protein assay kit) was separated electrophoretically using a 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gel and transferred to a nitrocellulose membrane. The membrane was incubated at room temperature in Odyssey blocking buffer including 0.05% Tween-20 containing primary antibodies as above directed to one of the following: SIRT 1 (1 :500), CLOCK (1 :2000), Bmall (1 : 1000), or β-actin (1 : 1000). After washing with TBS-T three times, the membrane was
incubated with anti -mouse or rabbit IRDye secondary antibodies (1 : 10,000) for 1 h at room temperature. Quantitative IR western blot detection was performed with Odyssey CLx Imager. Data were analyzed by one-way analysis of variance followed by post-hoc analysis of between group mean differences by Fisher's Least Significant Difference (LSD) test. Different superscripts indicate significant differences among groups (p < 0.05).
[0072] As illustrated in FIG. 3 A, SIRT1 levels are increased in OGD treated L-6 cells by RME and/or HFE. The quantified amounts of protein are illustrated in FIG. 3B demonstrating significantly increased amounts of SIRT1 levels relative to control. An additional effect is observed in RME+HFE mixture treated cells on SIRT1 expression, compared with individual RME or HFE only treated cells.
[0073] FIG. 4 illustrates CLOCK protein levels increased in OGD treated L-6 cells by RME and/or HFE. RME, HFE, or both significantly enhance CLOCK protein expression in OGD treated L6 skeletal muscle cells. An additional effect in RME+HFE mixture treated cells on CLOCK expression is also observed compared to individual RME or HFE only treated cells.
[0074] FIG. 5 illustrates Bmall protein levels increased in OGD treated L-6 cells by RME and/or HFE. RME, HFE, or both significantly enhance Bmall protein expression in OGD treated L-6 skeletal muscle cells. An additional effect is observed in cells treated with the RME+HFE compared with individual RME or HFE only treated cells.
[0075] Overall, a method for regulating expression of five key proteins linked to circadian rhythm disorders (CLOCK, BMAL1, FBXL3, FBXL21 and SIRT1) is described characterized by modulating expression in normal conditions and oxidative stress conditions in Rat Cr brain glioma cells, Rat L-6 myogenic cells, and IPEC-2 cells. Both extracts, RME and HFE, each significantly modulate the expression of circadian clock proteins in all cell types, and reverse cell damages identified by redcutions of the key proteins related to circadian rhythms induced by oxidative stress. These results indicate that RME and HFE extracts are useful as a new approach to attenuate the disruption of circadian rhythms, or to modulate circadian rhythm in a subject.
Ursolic acid enhances the expression of circadian rhythm proteins
[0076] iPEC-1 cells were grown as a monolayer in DMEM with 10% fetal bovine serum (FBS) and the necessary supplements at 37°C in a humidified incubator with 5% CO2. iPECl cells were seeded on 35 mm dishes. Experiments were initiated 48 hr after plating. Cells were treated with saline or with ursolic acid at three separate dosages (1 μΜ; 5 μΜ; or 20 μΜ) in the
medium for 24 hr at 37°C. The cells were then washed with ice-cold PBS and fixed with 4% paraformaldehyde for 10 min at room temperature followed by permeabilization with 0.3% Triton X-100 for 10 min. After being washed with PBS three times, cells were incubated for 1 hr in PBS containing 10% normal goat serum blocking solution. The cells were subjected to immunofluorescence staining with the target specific antibodies (SIRT1, CLOCK and Bmall) overnight at 4°C. The cells were then washed with cold PBS three times for 3 min each, and incubated with Alexa-labeled secondary antibodies (Invitrogen) at room temperature for 1 h. The cells were examined by fluorescence microscopy (a Nikon TE2000-S microscope, Nikon, Tokyo, Japan).
[0077] 24 hour incubation with ursolic acid significantly induced the intensity of immunofluorescence of SIRT1, CLOCK and Bmall compared with controls at all three concentrations of ursolic acid tested as evidenced by immunofluorescence staining.
[0078] Scientific and technical terms used herein are intended to have the meanings commonly understood by those of ordinary skill in the art. Such terms are found defined and used in context in various standard references illustratively including J. Sambrook and D.W. Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 3rd Ed., 2001; F.M. Ausubel, Ed., Short Protocols in Molecular Biology, Current Protocols; 5th Ed., 2002; B. Alberts et al., Molecular Biology of the Cell, 4th Ed., Garland, 2002; D.L. Nelson and M.M. Cox, Lehninger Principles of Biochemistry, 4th Ed., W.H. Freeman & Company, 2004; Wild, D., The Immunoassay Handbook, 3rd Ed., Elsevier Science, 2005; Gosling, J. P., Immunoassays: A Practical Approach, Practical Approach Series, Oxford University Press, 2005;Antibody Engineering, Kontermann, R. and Dubel, S. (Eds.), Springer, 2001; Harlow, E. and Lane, D., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988; Ausubel, F. et al., (Eds.), Short Protocols in Molecular Biology, Wiley, 2002; J. D. Pound (Ed.) Immunochemical Protocols, Methods in Molecular Biology, Humana Press; 2nd ed., 1998; B.K.C. Lo (Ed.), Antibody Engineering: Methods and Protocols, Methods in Molecular Biology, Humana Press, 2003; and Kohler, G. and Milstein, C, Nature, 256:495-497 (1975); the contents of each of which are incorporated herein by reference.
[0079] Methods involving conventional biological techniques are described herein. Such techniques are generally known in the art and are described in detail in methodology treatises such as Molecular Cloning: A Laboratory Manual, 3rd ed., vol. 1-3, ed. Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001 ; Current Protocols in
Molecular Biology, ed. Ausubel et al., Greene Publishing and Wiley-Interscience, New York, 1992 (with periodic updates); and Short Protocols in Molecular Biology, ed. Ausubel et al., 52 ed., Wiley-Interscience, New York, 2002. Immunological methods (e.g., preparation of antigen- specific antibodies, immunoprecipitation, and immunoblotting) are described, e.g., in Current Protocols in Immunology, ed. Coligan et al., John Wiley & Sons, New York, 1991 ; and Methods of Immunological Analysis, ed. Masseyeff et al., John Wiley & Sons, New York, 1992.
REFERENCES
1. Schulz P, Steimer T: Neurobiology of circadian systems. CNS. Drugs 23 Suppl 2:3-13,
2009
2. Buijs RM, Kalsbeek A: Hypothalamic integration of central and peripheral clocks.
NatRev.Neurosci. 2:521-526, 2001
3. Bray MS, Young ME: Circadian rhythms in the development of obesity: potential role for the circadian clock within the adipocyte. Obes.Rev. 8: 169-181, 2007
4. Gale JE, Cox HI, Qian J, et al: Disruption of circadian rhythms accelerates development of diabetes through pancreatic beta-cell loss and dysfunction. J.Biol.Rhythms 26:423- 433, 2011
5. Shaw E, Toiler GH: Circadian rhythm and cardiovascular disease. Curr.Atheroscler.Rep.
1 1 :289-295, 2009
6. Wyatt JK: Circadian rhythm sleep disorders. Pediatr.Clin.North Am. 58:621 -635, 201 1
7. Quera Salva MA, Hartley S, Barbot F, et al: Circadian rhythms, melatonin and depression.
Curr.Pharm.Des 17: 1459-1470, 2011
8. Schibler U, Ripperger J, Brown SA: Peripheral circadian oscillators in mammals: time and food. J.Biol.Rhythms 18:250-260, 2003
9. Jung-Hynes B, Ahmad N: SIRTl controls circadian clock circuitry and promotes cell survival: a connection with age-related neoplasms. FASEB J. 23:2803-2809, 2009
10. Chang HC, Guarente L: SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell 153: 1448-1460, 2013
1 1. Chang HC, Guarente L: SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell 153: 1448-1460, 2013 12. Hirano A, Yumimoto K, Tsunematsu R, et al: FBXL21 regulates oscillation of the circadian clock through ubiquitination and stabilization of cryptochromes. Cell 152: 1 106-11 18, 2013
13. Sanjust E, Mocci G, Zucca P, et al: Mediterranean shrubs as potential antioxidant sources.
Nat.Prod.Res. 22:689-708, 2008 14. Harach T, Aprikian O, Monnard I, et al: Rosemary (Rosmarinus officinalis L.) leaf extract limits weight gain and liver steatosis in mice fed a high-fat diet. Planta Med. 76:566-571, 2010
15. Tu Z, Moss-Pierce T, Ford P, et al: Rosemary (Rosmarinus officinalis L.) Extract Regulates
Glucose and Lipid Metabolism by Activating AMPK and PPAR Pathways in HepG2 Cells. J.Agric.Food Chem. 2013
16. Bakirel T, Bakirel U, Keles OU, et al: In vivo assessment of antidiabetic and antioxidant activities of rosemary (Rosmarinus officinalis) in alloxan-diabetic rabbits. J.Ethnopharmacol. 116:64-73, 2008
17. Uezu E: Effects of Hemerocallis on sleep in mice. Psychiatry Clin.Neurosci. 52: 136-137,
1998
18. Que F, Mao L, Zheng X: In vitro and vivo antioxidant activities of daylily flowers and the involvement of phenolic compounds. Asia Pac.J.Clin.Nutr. 16 Suppl 1 : 196-203, 2007
19. Wilking M, Ndiaye M, Mukhtar H, et al: Circadian rhythm connections to oxidative stress:
implications for human health. Antioxid.Redox. Signal. 19: 192-208, 2013
20. Hardeland R, Coto-Montes A, Poeggeler B: Circadian rhythms, oxidative stress, and antioxidative defense mechanisms. Chronobiol.Int. 20:921 -962, 2003.
21. U.S. Application Publication No: 201 1/0076349
22. WO 2001/080818 Al
[0080] Various modifications of the present invention, in addition to those shown and described herein, will be apparent to those skilled in the art of the above description. Such modifications are also intended to fall within the scope of the appended claims.
[0081] It is appreciated that all reagents are obtainable by sources known in the art unless otherwise specified.
[0082] Patents, publications, and applications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents, publications, and applications are incorporated herein by reference to the same extent as if each individual patent, publication, or application was specifically and individually incorporated herein by reference.
[0083] The foregoing description is illustrative of particular aspects of the invention, but is not meant to be a limitation upon the practice thereof. The following claims, including all equivalents thereof, are intended to define the scope of the invention.
Claims
1. A process of altering an expression characteristic of a CLOCK, BMALl, FBXL3, FBXL21, or SIRT1 protein in a subject comprising:
administering to said subject an effective amount of an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof at an administration time, said effective amount comprising ursolic acid at 10% or greater by weight;
said administration time occurring at or between -4 hours to 12 hours after light exposure.
2. The process of claim 1 said administration time is at or between 0 hours to 12 hours after light exposure.
3. The process of claim 1 said administration time is at or between 1 hours to 3 hours after light exposure or 10-14 hours after light exposure.
4. The process of claim 1 wherein said administration time is at or between -4 hours to 0 hours prior to light exposure.
5. A process for altering an expression characteristic of a circadian rhythm protein in a subject comprising:
administering to said subject an effective amount of an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof at an administration time;
said administration time occurring such that said extract, an active portion or component thereof, or combinations thereof, contacts a cell having a circadian rhythm thereby increasing the expression of CLOCK, BMALl, FBXL3, FBXL21, SIRT1, or combinations thereof in said subject.
6. The process of claim 5 wherein said extract is a water extract.
7. The process of claim 5 wherein extract, an active portion or component thereof, is a component in a dietary supplement.
8. The process of claim 5 wherein said administering is once daily.
9. The process of any one of claims 5-8 wherein said administration time is at or between -4 hours to 12 hours or 0 to 12 hours after light exposure.
10. The process of any one of claims 5-8 wherein said administration time is at or between 1-3 hours after light exposure or 10-14 hours after light exposure.
11. The process of any one of claims 5-8 wherein said administration time is at or between -4 hours to 0 hours prior to light exposure.
12. The process of any one of claims 5-8 wherein said extract is an extract of rosemary and said protein is the CLOCK protein.
13. The process of any one of claims 5-8 wherein said extract is an extract of rosemary and said protein is the BMAL1 protein.
14. The process of any one of claims 5-8 wherein said extract is an extract of rosemary and said protein is FBXL3, FBXL21, or combinations thereof.
15. The process of any one of claims 5-8 wherein said extract is an extract of rosemary and said protein is SIRT1.
16. The process of any one of claims 5-8 wherein said extract is an extract of hemerocallis fulva and said protein is CLOCK.
17. The process of any one of claims 5-8 wherein said extract is an extract of hemerocallis fulva and said protein is BMAL1.
18. The process of any one of claims 5-8 wherein said extract is an extract of hemerocallis fulva and said protein is FBXL3, FBXL21, or combinations thereof.
19. The process of any one of claims 5-8 wherein said extract is an extract of hemerocallis fulva and said protein is SIRT1.
20. The process of any one of claims 5-8 wherein said extract comprises 25% or greater ursolic acid.
21. A process for altering an expression characteristic of a circadian rhythm protein in a subject comprising:
administering to said subject an effective amount of ursolic acid at an administration time;
said administration time occurring such that said ursolic acid contacts a cell having a circadian rhythm thereby increasing the expression of CLOCK, BMALl, FBXL3, FBXL21, SIRT1, or combinations thereof in said subject.
22. The process of claim 21 wherein said ursolic acid is obtained from extracting the ursolic acid from rosemary, hemerocallis fulva, or combinations thereof with water, an alcohol or combinations thereof.
23. The process of claims 21 or 22 wherein said ursolic acid is a component in a dietary supplement.
24. The process of claim 21 wherein said administering is once daily.
25. The process of any one of claims 21-24 wherein said administration time is at or between -4 hours to 12 hours or 0 to 12 hours after light exposure.
26. The process of any one of claims 21-24 wherein said administration time is at or between 1-3 hours after light exposure or 10-14 hours after light exposure.
27. The process of any one of claims 21-24 wherein administration time is at or between -4 hours to 0 hours prior to light exposure.
28. The process of any one of claims 21 -24 wherein protein is the CLOCK protein.
29. The process of any one of claims 21-24 wherein said protein is the BMALl protein.
30. The process of any one of claims 21-24 wherein said protein is FBXL3, FBXL21, or combinations thereof.
31. The process of any one of claims 21 -24 wherein said protein is SIRT 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/036,479 US10039798B2 (en) | 2013-11-13 | 2014-11-13 | Extracts of rosemary or hemerocallis fulva and methods of using same to promote circadian rhythm |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361903440P | 2013-11-13 | 2013-11-13 | |
US201361903434P | 2013-11-13 | 2013-11-13 | |
US61/903,434 | 2013-11-13 | ||
US61/903,440 | 2013-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015073598A1 true WO2015073598A1 (en) | 2015-05-21 |
Family
ID=53057980
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/065374 WO2015073628A1 (en) | 2013-11-13 | 2014-11-13 | Treatment or prophylaxis of circadian protein related conditions |
PCT/US2014/065336 WO2015073598A1 (en) | 2013-11-13 | 2014-11-13 | Extracts of rosemary or hemerocallis fulva and methods of using same to promote circadian rhythm |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/065374 WO2015073628A1 (en) | 2013-11-13 | 2014-11-13 | Treatment or prophylaxis of circadian protein related conditions |
Country Status (5)
Country | Link |
---|---|
US (2) | US20160256511A1 (en) |
EP (1) | EP3068415A4 (en) |
JP (1) | JP6473759B2 (en) |
CN (1) | CN105979954A (en) |
WO (2) | WO2015073628A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6993819B2 (en) * | 2017-09-05 | 2022-01-14 | 株式会社ニップン | Circadian rhythm regulator |
WO2020000457A1 (en) * | 2018-06-29 | 2020-01-02 | 深圳市博奥康生物科技有限公司 | Grna targeting sequence that specifically targets human kat13d gene and use thereof |
EP3590359A1 (en) * | 2018-07-03 | 2020-01-08 | Centre National De La Recherche Scientifique | Taxodione for its use for protecting muscle and meat from oxidation |
TWI789553B (en) * | 2019-10-18 | 2023-01-11 | 大江生醫股份有限公司 | Use of hemerocallis fulva linn. extract for manufacturing of a composition for promoting skeletal muscle basal metaboilc rate |
CN111920735B (en) * | 2020-08-21 | 2022-02-08 | 广东盛普生命科技有限公司 | Plant-derived anti-aging composition and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060257386A1 (en) * | 2003-10-10 | 2006-11-16 | Zimmerman Amy C | Cosmetic composition and methods |
US20110076349A1 (en) * | 2008-05-30 | 2011-03-31 | Koichi Yoshihara | Composition containing hot-water extract of plant of the genus hemerocallis and having antidepressant-like effects or fatigue-relieving effects based on sleep improvement |
US20120183635A1 (en) * | 2006-11-24 | 2012-07-19 | Dsm Ip Assets B.V. | Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses |
WO2012142511A2 (en) * | 2011-04-15 | 2012-10-18 | Md Matrix Health Llc Dba Md Matrix Health Inc | Orthomolecular compositions and their use in stabilizing the extracellular matrix |
US20130237716A1 (en) * | 2012-03-07 | 2013-09-12 | Shiseido Company, Ltd. | Expression Modulator For Clock Gene |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094906A (en) * | 1993-05-12 | 1994-11-16 | 郑增问 | Fetus and infant's nutritious food capable of improving growth and development of brain structure |
JP4669920B2 (en) * | 2002-08-21 | 2011-04-13 | 沖縄県 | Functional material that suppresses blood glucose rise and blood pressure rise |
RU2275930C2 (en) * | 2004-04-26 | 2006-05-10 | ООО "РусГен" | Composition for correction of human endocrine system age-related changes (variants) and method for production of pharmaceutical formulation based on the same |
CN101405016B (en) * | 2006-04-07 | 2012-07-04 | 花王株式会社 | Lypolysis promoter |
EP1925214A1 (en) * | 2006-11-24 | 2008-05-28 | DSMIP Assets B.V. | Dietary and pharmaceutical compositions containing carnosol and/or rosmanol and their uses |
EP1925313A1 (en) * | 2006-11-24 | 2008-05-28 | Nestec S.A. | Prevention and treatment of disorders connected to impaired neurotransmission |
JP5414192B2 (en) * | 2007-03-29 | 2014-02-12 | 江崎グリコ株式会社 | Circadian rhythm adjustment composition |
CN101040901A (en) * | 2007-04-12 | 2007-09-26 | 云南龙润药业有限公司 | Rosmarinus officinalis extract and its preparing process and application |
US8703161B2 (en) * | 2007-08-13 | 2014-04-22 | Elc Management, Llc | Skin repair compositions comprising circadian gene activators and a synergistic combination of Sirt1 gene activators |
CN101422465A (en) * | 2007-10-30 | 2009-05-06 | 上海市新文达生物科技有限公司 | Use of ursolic acid and plant extract containing the same |
ES2584329T3 (en) * | 2010-03-31 | 2016-09-27 | Shiseido Company, Ltd. | Cosmetic use of Elemi oil to improve the rough skin resulting from the malfunction of the circadian rhythm |
CN103037692B (en) * | 2010-05-20 | 2015-02-25 | 爱荷华大学研究基金会 | Methods for inhibiting muscle atrophy |
JP5923238B2 (en) * | 2010-07-07 | 2016-05-24 | アサヒグループホールディングス株式会社 | Vagus nerve activator |
PT2661266T (en) * | 2011-01-07 | 2020-11-30 | Anji Pharma Us Llc | Chemosensory receptor ligand-based therapies |
CN102228250B (en) * | 2011-07-08 | 2012-12-19 | 北京工商大学 | Functional food for sleep improvement and preparation method thereof |
CN102416082B (en) * | 2011-11-10 | 2014-07-09 | 孙毅坤 | Traditional Chinese medicine extract used for treating insomnia |
-
2014
- 2014-11-13 US US14/431,097 patent/US20160256511A1/en not_active Abandoned
- 2014-11-13 JP JP2016554316A patent/JP6473759B2/en active Active
- 2014-11-13 WO PCT/US2014/065374 patent/WO2015073628A1/en active Application Filing
- 2014-11-13 EP EP14862727.6A patent/EP3068415A4/en not_active Withdrawn
- 2014-11-13 CN CN201480073023.3A patent/CN105979954A/en active Pending
- 2014-11-13 WO PCT/US2014/065336 patent/WO2015073598A1/en active Application Filing
- 2014-11-13 US US15/036,479 patent/US10039798B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060257386A1 (en) * | 2003-10-10 | 2006-11-16 | Zimmerman Amy C | Cosmetic composition and methods |
US20120183635A1 (en) * | 2006-11-24 | 2012-07-19 | Dsm Ip Assets B.V. | Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses |
US20110076349A1 (en) * | 2008-05-30 | 2011-03-31 | Koichi Yoshihara | Composition containing hot-water extract of plant of the genus hemerocallis and having antidepressant-like effects or fatigue-relieving effects based on sleep improvement |
WO2012142511A2 (en) * | 2011-04-15 | 2012-10-18 | Md Matrix Health Llc Dba Md Matrix Health Inc | Orthomolecular compositions and their use in stabilizing the extracellular matrix |
US20130237716A1 (en) * | 2012-03-07 | 2013-09-12 | Shiseido Company, Ltd. | Expression Modulator For Clock Gene |
Also Published As
Publication number | Publication date |
---|---|
US20160256511A1 (en) | 2016-09-08 |
JP2016537426A (en) | 2016-12-01 |
EP3068415A1 (en) | 2016-09-21 |
US20160296581A1 (en) | 2016-10-13 |
CN105979954A (en) | 2016-09-28 |
US10039798B2 (en) | 2018-08-07 |
WO2015073628A1 (en) | 2015-05-21 |
JP6473759B2 (en) | 2019-02-20 |
EP3068415A4 (en) | 2017-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10039798B2 (en) | Extracts of rosemary or hemerocallis fulva and methods of using same to promote circadian rhythm | |
Kawano et al. | Hypoglycemic effect of aspalathin, a rooibos tea component from Aspalathus linearis, in type 2 diabetic model db/db mice | |
Jiménez et al. | Epicatechin: endothelial function and blood pressure | |
Kang et al. | A water-soluble extract of Petalonia binghamiae inhibits the expression of adipogenic regulators in 3T3-L1 preadipocytes and reduces adiposity and weight gain in rats fed a high-fat diet | |
JP5271534B2 (en) | Muscle atrophy inhibitor | |
CA3023426A1 (en) | Dietary supplements and compositions for enhancing physical performance and energy levels | |
KR20160139072A (en) | Pharmaceutical composition comprising Ptentilla Chinensis extract or isolated polyphenolic compounds for prevention or treatment of metabolic disease | |
He et al. | Anti-inflammatory activity of peptides derived from millet bran in vitro and in vivo | |
Kim et al. | Gynostemma pentaphyllum extract and Gypenoside L enhance skeletal muscle differentiation and mitochondrial metabolism by activating the PGC-1α pathway in C2C12 myotubes | |
Tripodi et al. | Protective effect of Vigna unguiculata extract against aging and neurodegeneration | |
Diniz et al. | Potential therapeutic role of dietary supplementation with spirulina platensis on the erectile function of obese rats fed a hypercaloric diet | |
KR20150071932A (en) | Pharmaceutical composition containing TAZ modulator for mygeonic differentiation and muscle regeneration | |
CN108697723A (en) | Beggar-ticks is to increasing muscle and reducing the advantageous effect of fat | |
KR101637433B1 (en) | -- Composition for preventing or treating neurodegenerative disease containing -iso-cubebene | |
JP6557893B1 (en) | Composition for prevention, reduction and / or treatment of heat stroke | |
Kim et al. | Whole red paprika (Capsicum annuum L.) and its orange-red pigment capsanthin ameliorate obesity-induced skeletal muscle atrophy in mice | |
US20160354331A1 (en) | Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellullar senescence produced by diabetis and other degenerative chronic complex diseases | |
KR101637429B1 (en) | -- Composition for preventing or treating neurodegenerative disease containing -iso-cubebenol | |
TWI484973B (en) | Mixture from fermentation of anoectochilus formosanus hayata by microorganism and use thereof | |
RU2765414C1 (en) | Method for stimulating mitophagy and autophagy in cells, method for stimulating autophagy or mitophagy for treating a condition associated with mitochondrial dysfunction | |
KR20160023965A (en) | Pharmaceutical composition for muscle regeneration comprising ursolic acid and leucine | |
Collin | 3T3-L1 adipocytes as a model of Glut4 translocation | |
Pathiranalage | Anti-inflammatory and foam cell formation inhibitory activities of ark shell (Scapharca subcrenata) hydrolysates in murine macrophages | |
AU2021204964A1 (en) | Composition for use in the treatment of cognitive disorders | |
KR20210127655A (en) | Composition for preventing or treating obesity comprising Grateloupia elliptica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14862815 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15036479 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14862815 Country of ref document: EP Kind code of ref document: A1 |